Adaptimmune Therapeutics Plc (ADAPY)
0.0026
0.00 (0.00%)
USD |
OTCM |
May 07, 16:00
Adaptimmune Therapeutics Research and Development Expense (Annual) : 160.54M for Dec. 31, 2024
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Silence Therapeutics Plc | 60.29M |
| Biodexa Pharmaceuticals Plc | 5.026M |
| Oxford Biomedica Plc | 82.72M |
| NuCana Plc | 16.79M |
| Autolus Therapeutics Plc | 128.59M |